We are live on ! Find out more
KCM

Kalehua Capital Management Portfolio holdings

AUM $174M
This Fund
S&P 500
This Quarter Est. Return
+45.16%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$174M
AUM Growth
+$32.6M
Cap. Flow
+$3.44M
Cap. Flow %
1.98%
Top 10 Hldgs %
70.75%
Holding
33
New
8
Increased
3
Reduced
2
Closed
7

Top Buys

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$5.95M
2
IFRX icon
InflaRx
IFRX
+$5.45M
3
CYCN icon
Cyclerion Therapeutics
CYCN
+$5.36M
4
KRRO icon
Korro Bio
KRRO
+$3.67M
5
ANL
Adlai Nortye Group ADS
ANL
+$2.76M

Top Sells

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$8.97M
2
ORKA
Oruka Therapeutics
ORKA
+$5.81M
3
QURE icon
uniQure
QURE
+$5.54M
4
PEPG icon
PepGen
PEPG
+$1.77M
5
TNYA icon
Tenaya Therapeutics
TNYA
+$1.38M

Sector Composition

Rank Sector Weight
1 Healthcare 84.78%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOXX icon
1
Alpha Architect 1-3 Month Box ETF
BOXX
$14B
$26.5M 15.22%
226,188
+7,910
+4% +$923K
MANE
2
Veradermics Inc
MANE
$4.11B
$17.9M 10.3%
145,695
– –
XFOR icon
3
X4 Pharmaceuticals
XFOR
$402M
$17.4M 9.99%
3,722,840
– –
CMPS
4
Compass Pathways
CMPS
$1.97B
$11.6M 6.67%
819,692
– –
SRZN icon
5
Surrozen
SRZN
$282M
$10M 5.75%
385,178
– –
ACRS icon
6
Aclaris Therapeutics
ACRS
$929M
$9.69M 5.57%
1,832,365
– –
SION
7
Sionna Therapeutics
SION
$253M
$8.67M 4.98%
197,072
– –
IKT icon
8
Inhibikase Therapeutics
IKT
$349M
$7.76M 4.46%
3,821,890
– –
PHVS icon
9
Pharvaris
PHVS
$2.62B
$6.87M 3.95%
198,772
– –
KPTI icon
10
Karyopharm Therapeutics
KPTI
$42.2M
$6.7M 3.85%
+685,644
New +$5.95M
SEPN
11
Septerna Inc
SEPN
$1.89B
$6.52M 3.75%
194,544
– –
IFRX icon
12
InflaRx
IFRX
$302M
$6.49M 3.73%
+2,897,769
New +$5.45M
CYCN icon
13
Cyclerion Therapeutics
CYCN
$18.4M
$5.6M 3.22%
+1,651,350
New +$5.36M
KRRO icon
14
Korro Bio
KRRO
$192M
$5.34M 3.07%
405,040
+295,664
+270% +$3.67M
QURE icon
15
uniQure
QURE
$3.29B
$3.66M 2.1%
79,407
-211,702
-73% -$5.54M
LONA
16
LeonaBio Inc
LONA
$72.8M
$3.62M 2.08%
393,701
– –
DMRA
17
Damora Therapeutics
DMRA
$1.87B
$3.62M 2.08%
139,000
– –
MLTX icon
18
MoonLake Immunotherapeutics
MLTX
$1.31B
$3.42M 1.97%
175,734
– –
ANL
19
Adlai Nortye Group ADS
ANL
$912M
$2.6M 1.5%
+226,415
New +$2.76M
TYRA icon
20
Tyra Biosciences
TYRA
$1.56B
$2.38M 1.37%
74,465
– –
NVCT icon
21
Nuvectis Pharma
NVCT
$779M
$1.84M 1.06%
+100,000
New +$1.12M
GOSS icon
22
Gossamer Bio
GOSS
$85.5M
$1.84M 1.05%
11,149,363
+913,070
+9% +$255K
MIST icon
23
Milestone Pharmaceuticals
MIST
$129M
$1.7M 0.98%
+1,269,237
New +$2.03M
ATYR
24
aTyr Pharma
ATYR
$52M
$1.07M 0.61%
+1,788,167
New +$1.17M
TIL icon
25
Instil Bio
TIL
$53M
$766K 0.44%
99,600
-83,430
-46% -$673K
1
2

Similar funds

PWSG
Pacific Wealth Strategies Group Santa Barbara, California $174M AUM 21.47% 1-Year Est. Return
6SA
6th Street Advisors Daphne, Alabama $174M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $174M AUM
PIA
Prakash Investment Advisors Andover, Massachusetts $174M AUM 85.35% 1-Year Est. Return
CPCP
Cedar Point Capital Partners Cedar Rapids, Iowa $174M AUM 19.71% 1-Year Est. Return
PMSA
Patrick M. Sweeney & Associates Libertyville, Illinois $174M AUM 29.38% 1-Year Est. Return
MCM
MontVue Capital Management Lynchburg, Virginia $174M AUM 24.95% 1-Year Est. Return
AIA
Accelerate Investment Advisors Aliso Viejo, California $174M AUM 23.04% 1-Year Est. Return

Kalehua Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Kalehua Capital Management held 33 positions worth $174M, up 23% from $141M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Kalehua Capital Management's Q2 2026 filing shows 8 new, 3 increased, 2 reduced and 7 closed positions. Its largest new stake was Karyopharm Therapeutics: 685,644 shares worth $6.7M. The largest sale was Relay Therapeutics, an estimated $8.97M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Materials.

  • Kalehua Capital Management's largest Q2 2026 buy was Karyopharm Therapeutics: 685,644 shares worth $6.7M.
  • Kalehua Capital Management added most to Korro Bio in Q2 2026, an estimated $3.67M increase.
  • Kalehua Capital Management's biggest Q2 2026 reduction was uniQure, cutting an estimated $5.54M.
  • Kalehua Capital Management fully exited Relay Therapeutics in Q2 2026, selling an estimated $8.97M.
  • Kalehua Capital Management's ten largest holdings make up 71% of its $174M portfolio in Q2 2026.
  • Kalehua Capital Management opened 8 new positions and closed 7 in Q2 2026.
  • Kalehua Capital Management's portfolio value rose 23% quarter-over-quarter to $174M.

Based on Kalehua Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.